{"id":"W4408682588","doi":"10.1177/17588359251326710","title":"Clinician’s guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Occupational Cancer Research Centre; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; Novartis Pharmaceuticals Canada; Genentech; Astellas Pharma; Seagen; University of Toronto; Genomic Health; F. Hoffmann-La Roche; Purdue University; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Novartis; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Adverse effect; Discontinuation; Breast cancer; Adjuvant; Oncology; Clinical trial; Disease; Internal medicine; Cancer; Intensive care medicine; Quality of life (healthcare); Metastatic breast cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004990231,0.0007259228,0.003607436,0.0005865451,0.00005313725,0.000008199877,0.0006364249,0.0008811424,0.0003737802],"category_scores_gemma":[0.0003712701,0.0003882208,0.0002939219,0.001262023,0.001178387,0.0002161692,0.0001472754,0.001945143,0.000009560161],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001354828,"about_ca_system_score_gemma":0.002900684,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001601554,"about_ca_topic_score_gemma":0.0005527445,"domain_scores_codex":[0.9945298,0.0009468187,0.001926287,0.000813352,0.0011423,0.0006414236],"domain_scores_gemma":[0.9936411,0.004194058,0.0009125696,0.0008340865,0.0002154743,0.0002027536],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001577558,0.0009730632,0.002369007,0.001931,0.0002480342,0.00008176141,0.0003540844,0.00001102992,7.448667e-8,0.0003329482,0.00006504626,0.9920564],"study_design_scores_gemma":[0.00382565,0.001179428,0.002106447,0.04917484,0.0002596336,0.00002052343,0.00006124278,0.000004839799,9.012174e-7,0.0001676266,0.9428617,0.0003372164],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0005392155,0.9938533,0.00007988824,0.001596197,0.0009776891,0.002404107,0.00005455545,0.00003956714,0.0004555217],"genre_scores_gemma":[0.000687691,0.9916304,0.0002888541,0.005811051,0.0003558671,0.0009114409,0.00003173695,0.00008998815,0.0001930071],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9917192,"threshold_uncertainty_score":0.9998569,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05930661329680937,"score_gpt":0.4257630122102647,"score_spread":0.3664563989134554,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}